Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201915 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT01201915 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 74 participants.
The verdict
NCT01201915, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
Interventions
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01201915
The ClinicalTrials.gov registry entry for NCT01201915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vismodegib is the first listed.
NCT01201915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01201915 about?
NCT01201915 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma". This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
What is the current status of trial NCT01201915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2010-10. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01201915?
The interventions under investigation include: Vismodegib (DRUG).
Who is sponsoring clinical trial NCT01201915?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.